MedTrace Logo

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC

NCT03732001 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-11-28

No results posted yet for this study

Summary

Evaluate the efficacy and safety of Anlotinib in combination with Docetaxel versus Docetaxel in patients with advanced non-small lung cancer after failure of first-line Chemotherapy .

Conditions

Interventions

DRUG

Anlotinib combined Docetaxel

Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)

DRUG

Docetaxel

Docetaxel (75mg/m2, IV, d1, 21 days per cycle)

Sponsors & Collaborators

  • Shengjing Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • General Hospital of Shenyang Military Region

    collaborator OTHER

  • The People's Hospital of Liaoning Province

    collaborator OTHER

  • Shenyang Chest Hospital

    collaborator OTHER

  • Anshan Tumor Hospital

    collaborator OTHER

  • Affiliated Zhongshan Hospital of Dalian University

    collaborator OTHER

  • The First People's Hospital of Jingzhou

    collaborator OTHER

  • Benxi Cental Hospital

    collaborator OTHER

  • Panjin Liaohe Oilfield Gem Flower Hospital

    collaborator OTHER

  • Panjin Central Hospital

    collaborator OTHER

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, PhD · China Medical University, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-08
Primary Completion
2019-11-09
Completion
2020-11-09

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03732001 on ClinicalTrials.gov